Cartesian Therapeutics Inc (RNAC)
26.41
+0.07
(+0.27%)
USD |
NASDAQ |
May 17, 16:00
26.41
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Revenue (Quarterly): 5.84M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 5.84M |
| December 31, 2023 | 8.266M |
| September 30, 2023 | 6.551M |
| June 30, 2023 | 5.249M |
| March 31, 2023 | 5.938M |
| December 31, 2022 | 16.80M |
| September 30, 2022 | 20.71M |
| June 30, 2022 | 39.27M |
| March 31, 2022 | 34.00M |
| December 31, 2021 | 29.94M |
| September 30, 2021 | 24.43M |
| June 30, 2021 | 19.66M |
| March 31, 2021 | 11.05M |
| December 31, 2020 | 11.95M |
| September 30, 2020 | 4.646M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 6.654M |
| September 30, 2019 |
| Date | Value |
|---|---|
| June 30, 2019 | 0.013M |
| March 31, 2019 | 0.01M |
| December 31, 2018 | 0.903M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 0.017M |
| September 30, 2017 | 0.027M |
| June 30, 2017 | 0.026M |
| March 31, 2017 | 0.137M |
| December 31, 2016 | 2.93M |
| September 30, 2016 | 1.048M |
| June 30, 2016 | 2.017M |
| March 31, 2016 | 2.088M |
| December 31, 2015 | 2.134M |
| September 30, 2015 | 1.607M |
| June 30, 2015 | 1.236M |
| March 31, 2015 | 1.034M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.013M
Minimum
Jun 2019
39.27M
Maximum
Jun 2022
14.76M
Average
11.05M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
| Marinus Pharmaceuticals Inc | 7.679M |
| Adial Pharmaceuticals Inc | -- |
| Poseida Therapeutics Inc | 28.14M |
| Biomea Fusion Inc | -- |
| NovaBay Pharmaceuticals Inc | 2.631M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -56.82M |
| Total Expenses (Quarterly) | 19.19M |
| EPS Diluted (Quarterly) | -10.50 |
| Enterprise Value | 366.93M |
| Profit Margin (Quarterly) | -973.0% |
| Earnings Yield | -212.3% |
| Normalized Earnings Yield | -87.52 |